Alcobra plummets on MDX Phase III failure

Shares of Israeli pharma firm Alcobra (Nasdaq: ADHD) went into free fall in pre-market US trading today, after it reported disappointing top-line results from MEASURE, its second Phase III clinical trial for the investigational product metadoxine extended release (MDX) for the treatment of attention deficit hyperactivity disorder (ADHD) in adult patients. The stock plunged 52.6% to $1.90.

In this trial, MDX did not meet the primary endpoint of demonstrating a statistically-significant difference from placebo in the change from baseline of the investigator rating of the Conners’ Adult ADHD Rating Scales (CAARS).

As previously communicated, the top-line data analysis was conducted on the Full Analysis Set (n=283), which includes all randomized subjects with at least one post-baseline efficacy assessment. Consistent with previously conducted studies, MDX was generally well tolerated.